SCHEMBL2844937

SCHEMBL2844937

CC(C)CC(CC(=O)O)CC(C)CC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.63
CACNB3 P54284 1/20 0.63
CACNA1C Q13936 1/20 0.63
PGR P06401 1/20 0.63
ADRA1A P35348 1/20 0.63
HTR2B P41595 1/20 0.63
CACNA2D2 Q9NY47 1/20 0.63
RNPEP Q9H4A4 1/20 0.38
SLC7A5 Q01650 1/20 0.38
MME P08473 2/20 0.37
BHMT Q93088 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
ALDH1A1 P00352 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412290 0.91 CACNA2D1 (0.74) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL11762538 0.88 CACNA2D1 (0.71) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL968570 0.85 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL5536469 0.85 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL1410027 0.85 CACNA2D1 (0.74) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL3783223 0.83 CACNA2D1 (0.52) CACNA2D1CACNB3CACNA1CPGRADRA1A
Ammonia Solution, Strong SCHEMBL28027924 0.83 CACNA2D1 (0.52) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL2171052 0.81 CACNA2D1 (0.50) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL14359978 0.80 CACNA2D1 (0.46) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL12878966 0.79 CACNA2D1 (0.65) CACNA2D1CACNB3CACNA1CPGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2174958-A1 Antibodies derived from anti ed-b l19 and targeting tumor vasculature Philogen S.p.A. (IT) 2010-04-14 EP disclosed
CN-100482285-C Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ED-B PHILOGEN S P A SCHERING AG (IT) 2009-04-29 CN disclosed
CN-1849144-A Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ED-B PHILOGEN SPA (IT) 2006-10-18 CN disclosed
EP-1663320-A1 TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B Philogen S.p.A. (IT) 2006-06-07 EP disclosed
WO-2003076469-A9 ANTIBODIES DERIVED ROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE PHILOGEN SPA (IT) 2005-09-29 WO disclosed
WO-2005023318-A1 TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B PHILOGEN S.P.A (IT) 2005-03-17 WO disclosed
EP-1483297-A2 ANTIBODIES DERIVED FROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE Philogen S.p.A. (IT) 2004-12-08 EP disclosed
WO-2003076469-A2 ANTIBODIES DERIVED ROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE PHILOGEN S.P.A. (IT) 2003-09-18 WO disclosed